Terns Pharmaceuticals (NASDAQ:TERN) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Terns Pharmaceuticals (NASDAQ:TERN) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Other equities research analysts have also issued reports about the company. Oppenheimer lifted their price objective on Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Citizens Jmp upped their target price on Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Monday, December 29th. Barclays boosted their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Finally, William Blair raised Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.56.

Terns Pharmaceuticals Stock Performance

TERN stock opened at $36.60 on Friday. The company has a market capitalization of $3.30 billion, a P/E ratio of -35.53 and a beta of -0.28. The company has a fifty day moving average price of $34.85 and a 200-day moving average price of $17.21. Terns Pharmaceuticals has a 52-week low of $1.87 and a 52-week high of $48.26.

Terns Pharmaceuticals (NASDAQ:TERN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. As a group, sell-side analysts forecast that Terns Pharmaceuticals will post -1.19 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jill M. Quigley sold 24,520 shares of Terns Pharmaceuticals stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the transaction, the insider directly owned 50,365 shares in the company, valued at approximately $1,942,578.05. The trade was a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 165,763 shares of company stock valued at $5,752,450 in the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Terns Pharmaceuticals

Several large investors have recently modified their holdings of TERN. FNY Investment Advisers LLC purchased a new stake in shares of Terns Pharmaceuticals in the fourth quarter valued at approximately $80,000. Tema Etfs LLC acquired a new stake in Terns Pharmaceuticals during the 4th quarter valued at $414,000. SG Americas Securities LLC bought a new position in Terns Pharmaceuticals during the 4th quarter valued at $1,772,000. GAMMA Investing LLC boosted its holdings in shares of Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after buying an additional 770 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Terns Pharmaceuticals by 90.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 682,708 shares of the company’s stock valued at $5,127,000 after purchasing an additional 324,502 shares during the last quarter. 98.26% of the stock is owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing oral small?molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.